期刊
MAYO CLINIC PROCEEDINGS
卷 87, 期 11, 页码 1106-1117出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2012.07.016
关键词
-
Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection. (C) 2012 Mayo Foundation for Medical Education and Research square Mayo Gin Proc. 2012:87(11):1106-1117
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据